Improvement of physical activity in chronic obstructive pulmonary disease by pulmonary rehabilitation and pharmacological treatment

Shioya, Takanobu; Sato, Susumu; Iwakura, Masahiro; Takahashi, Hitomi; Terui, Yoshino; Uemura, Sachiko; Satake, Masahiro

doi:10.1016/j.resinv.2018.05.002

Cited by 15 publications

(11 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PR programs often fail to achieve sustained and significant increases in PA [55,56]. Individualised, tailored exercise programs enhance the adherence to PA [36].…”

Section: Discussionmentioning

confidence: 99%

Physical Activity and Sedentary Behaviour Patterns in 326 Persons with COPD before Starting a Pulmonary Rehabilitation: A Cluster Analysis

Geidl

Carl

Cassar

et al. 2019

JCM

View full text Add to dashboard Cite

This study applies a cluster analysis to identify typical physical activity (PA) and sedentary behaviour (SB) patterns in people with chronic obstructive pulmonary disease (COPD) before starting pulmonary rehabilitation (PR). We implemented an observational design which assessed baseline data of objectively measured PA and SB from the STAR (Stay Active after Rehabilitation) study. A total of 355 persons wore an accelerometer (Actigraph wGT3X) for seven days before the start of their PR. Sociodemographic and disease-related parameters were assessed at the start of PR. We applied cluster analysis and compared clusters applying univariate variance analyses. Data was available for 326 persons (31.6% women; age ø = 58 years). Cluster analysis revealed four movement clusters with distinct PA and SB patterns: Sedentary non-movers (28.5%), sedentary occasional movers (41.7%), sedentary movers (19.6%), and sedentary exercisers (10.1%). The four clusters displayed varying levels of moderate PA before rehabilitation (Ø daily min: 9; 28; 38; 70). Notably, all four clusters displayed considerably long average sedentary time per day (Ø daily minutes: 644; 561; 490; 446). The clusters differed significantly in disease-related parameters of GOLD severity, FEV1, CAT, and 6-Min-Walk-Test. In addition to PA promotion, PR programs should consider the reduction of sedentary behaviour as a valuable goal.

show abstract

“…PR programs often fail to achieve sustained and significant increases in PA [55,56]. Individualised, tailored exercise programs enhance the adherence to PA [36].…”

Section: Discussionmentioning

confidence: 99%

Physical Activity and Sedentary Behaviour Patterns in 326 Persons with COPD before Starting a Pulmonary Rehabilitation: A Cluster Analysis

Geidl

Carl

Cassar

et al. 2019

JCM

View full text Add to dashboard Cite

show abstract

“…Data from randomized controlled clinical trials have shown an increase in exercise endurance with dual bronchodilator therapy compared with monotherapy 15. Nevertheless, it is still not clear whether the observed effects on exercise capacity translate to true changes in daily physical activity in patients 40,41…”

Section: Discussionmentioning

confidence: 99%

<p>Improvement In Self-Reported Physical Functioning With Tiotropium/Olodaterol In Central And Eastern European COPD Patients</p>

Valipour

Tamm

Kociánová³

et al. 2019

COPD

View full text Add to dashboard Cite

BackgroundReduced physical activity is associated with increased morbidity and mortality in patients with COPD. Studies suggest that treatment with the long-acting muscarinic antagonist tiotropium and the long-acting β2-agonist olodaterol increases exercise capacity. This study assessed the effects of a fixed-dose combination (FDC) of tiotropium/olodaterol (delivered via Respimat®) on physical functioning in patients with stable COPD in a “real-world setting”.MethodsAn international, open-label, single-arm, non-interventional study conducted in nine countries measuring changes in self-reported physical functioning in COPD patients treated with tiotropium/olodaterol 5/5 μg FDC for approximately 6 weeks. The primary endpoint was therapeutic success, defined as a minimum 10-point increase in the 10-question Physical Functioning Questionnaire (PF-10) score. Secondary endpoints included absolute change in PF-10 from Visit 1 to Visit 2, patient general condition (measured by Physician’s Global Evaluation score) and patient satisfaction with the treatment and device (assessed by Patient Satisfaction Questionnaire at the end of the study period).ResultsTherapeutic success was observed in 67.8% of 7218 patients (95% CI 66.7, 68.8) in the final analysis set after approximately 6 weeks of treatment with tiotropium/olodaterol. Mean change in PF-10 score between Visit 1 and Visit 2 was 16.6 points (95% CI 16.2, 17.0). Therapeutic success was 64.3% (95% CI 63.0–65.6%) in patients with infrequent (≤1) and 76.1% (95% CI 74.3–77.9%) in patients with frequent (≥2) exacerbations (p<0.0001). Patient general condition improved as indicated by an improvement in Physician’s Global Evaluation scores between visits. Most patients were very satisfied or satisfied with tiotropium/olodaterol treatment in general (81%), reported inhalation satisfaction (85%), and satisfactory handling of the device (84%). 1.3% of patients reported an investigator-defined drug-related adverse event.ConclusionTreatment with tiotropium/olodaterol led to an improvement in self-reported physical functioning in patients with COPD.

show abstract

“…Despite this, the reduction of physical activity is very common in COPD, even starting from the GOLD stage I [7]. Several interventions can be established to increase physical activity and adequate bronchodilator inhalation therapy is one of the most important among them [8][9][10].…”

Section: Introductionmentioning

confidence: 99%

Physical Functioning in Patients with Chronic Obstructive Pulmonary Disease Treated with Tiotropium/Olodaterol Respimat in Routine Clinical Practice in Italy

et al. 2020

View full text Add to dashboard Cite

Introduction: Clinical studies have shown significant improvements in exercise capacity in patients with chronic obstructive pulmonary disease (COPD) who are treated with a tiotropium/ olodaterol fixed-dose combination (FDC). However, the effects of this treatment, which is administered in a single device, on physical functioning in a real-life setting of patients with COPD had not been fully determined.Methods: An open-label, observational study was conducted in 309 patients with COPD from 29 sites across Italy who received tiotropium/ olodaterol FDC for 6 weeks. Physical functioning was evaluated using the Physical Functioning Questionnaire (PF-10). The primary endpoint was the proportion of patients with therapeutic success, defined as a ten-point increase in the PF-10 score from the baseline visit. Secondary endpoints were absolute changes in PF-10 score from baseline visit, the patient's general condition assessed by the Physician's Global Evaluation (PGE) score, and patient satisfaction with treatment, inhaling and handling of the device. Results: According to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) multimodality assessment, most patients were Digital Features To view digital features for this article go to

show abstract

Improvement of physical activity in chronic obstructive pulmonary disease by pulmonary rehabilitation and pharmacological treatment

Cited by 15 publications

References 79 publications

Physical Activity and Sedentary Behaviour Patterns in 326 Persons with COPD before Starting a Pulmonary Rehabilitation: A Cluster Analysis

Physical Activity and Sedentary Behaviour Patterns in 326 Persons with COPD before Starting a Pulmonary Rehabilitation: A Cluster Analysis

<p>Improvement In Self-Reported Physical Functioning With Tiotropium/Olodaterol In Central And Eastern European COPD Patients</p>

Physical Functioning in Patients with Chronic Obstructive Pulmonary Disease Treated with Tiotropium/Olodaterol Respimat in Routine Clinical Practice in Italy

Contact Info

Product

Resources

About